Neuroendocrine tumors - Pipeline Insight, 2025

DelveInsight’s, “Neuroendocrine tumors - Pipeline Insight, 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Neuroendocrine tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Neuroendocrine tumors: Understanding

Neuroendocrine tumors: Overview

A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have a specific effect on the activity of other organs or cells in the body. Most NETs take years to develop and grow slowly.

Neuroendocrine tumors may be functional or nonfunctional, depending on their hormone secretion. Functional NETs produce excess hormones, while nonfunctional tumors don’t produce hormones or enough of them to cause noticeable symptoms. Which hormone or hormones the cancer cells secrete depends on where the cancer develops. About 60 percent of NETs are categorized as nonfunctional, according to the American Society of Clinical Oncology (ASCO). The symptoms of the NET and the treatment plan will likely depend on whether the tumor is functional or nonfunctional.

Neuroendocrine tumors (NETs) can be discovered for many different reasons because there is no single set of common symptoms. Symptoms are changes that one can feel in their body. In its early stages, a NET often causes no symptoms and may only be detected during an unrelated x-ray or surgery for another condition. If a person with a NET has symptoms, those symptoms may be associated with the size and/or location of the tumor or with the release of hormones, such as carcinoid syndrome.

The diagnosis of a NET requires a coordinated multidisciplinary effort involving medical oncologists, surgeons, interventional radiologists and pathologists. Results from pathology testing, hormonal testing, and diagnostic and functional imaging are integrated to form a comprehensive diagnostic picture. Surgery is the removal of the tumor and some surrounding healthy tissue during an operation. A surgical oncologist is a doctor who specializes in cancer surgery. Completely removing the entire tumor is the standard treatment, when possible. Most localized NETs are successfully treated with surgery alone. The surgeon will usually remove some tissue surrounding the tumor, called a margin, in an effort to leave no traces of cancer in the body.

""Neuroendocrine tumors- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neuroendocrine tumors pipeline landscape is provided which includes the disease overview and Neuroendocrine tumors treatment guidelines. The assessment part of the report embraces, in depth Neuroendocrine tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuroendocrine tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Neuroendocrine tumors R&D. The therapies under development are focused on novel approaches to treat/improve Neuroendocrine tumors.

Neuroendocrine tumors Emerging Drugs Chapters

This segment of the Neuroendocrine tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neuroendocrine tumors Emerging Drugs

RYZ101: RayzeBio, Inc.

RYZ101 is an investigational, targeted RPT designed to deliver a highly potent alpha-emitting radioisotope, Actinium-225 (Ac225), to solid tumors expressing SSTR2. RYZ101 leverages DOTATATE, a known binder and linker used in other radiopharmaceutical produts. RYZ101 uses Ac225 instead of the Lu177 used in Lutathera and thus delivers hundreds of times more potency in cancer cell killing. The higher potency of RYZ101 can provide significant clinical benefit to patients. RYZ101 utilizes a proprietary and patent protected formulation. The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors. Currently, the drug is in the Phase III stage of development to treat neuroendocrine tumors.

CAM2029: Camurus

CAM2029 is a long-acting subcutaneous depot of octreotide under development for the treatment of three rare diseases: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET) and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen device. Currently, the drug is in the Phase III stage of its development for the treatment of gastroentero pancreatic neuroendocrine tumors.

Ramucirumab: Eli Lilly and Company

Ramucirumab is a fully human IgG1 monoclonal antibody receptor antagonist designed to bind the extracellular domain of vascular endothelial growth factor (VEGF) receptor-2, thereby blocking the interaction of VEGF ligands (VEGF-A, VEGF-C, and VEGF-D) and inhibiting receptor activation. VEGF receptor-2 is considered a primary mediator of angiogenesis. When activated by VEGF ligands, VEGF receptor-2 promotes endothelial cell proliferation and survival, migration, and vascular permeability. Ramucirumab, which Lilly gained through its 2008 acquisition of ImClone Systems, is being investigated in clinical trials as monotherapy and in combination with other anticancer therapies for the treatment of multiple types of cancer. Currently, the drug is in the Phase II stage of its development for the treatment of neuroendocrine tumors.

Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

ADCT-701: ADC Therapeutics

ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK-1, site-specifically conjugated using Glycoconnect technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1, while its potency was strongly reduced in DLK-1-negative cell lines. In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity compared to the vehicle- and isotype control ADC-treated mice. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

Further product details are provided in the report……..

Neuroendocrine tumors: Therapeutic Assessment

This segment of the report provides insights about the different Neuroendocrine tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Neuroendocrine tumors

There are approx. 100+ key companies which are developing the therapies for Neuroendocrine tumors. The companies which have their Neuroendocrine tumors drug candidates in the most advanced stage, i.e. Phase III include, RayzeBio, Inc.

Phases

DelveInsight’s report covers around 120+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Neuroendocrine tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neuroendocrine tumors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neuroendocrine tumors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuroendocrine tumors drugs.

Neuroendocrine tumors Report Insights

Neuroendocrine tumors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Neuroendocrine tumors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Neuroendocrine tumors drugs?

How many Neuroendocrine tumors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neuroendocrine tumors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neuroendocrine tumors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Neuroendocrine tumors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

RayzeBio, Inc.

Camurus

Vyriad, Inc.

ADC Therapeutics

Eli Lilly and Company

Biotheus Inc.

ImmunityBio, Inc.

Chimerix

Merck Sharp & Dohme

Oryzon Genomics S.A.

CSPC ZhongQi Pharmaceutical Technology

TaiRx, Inc.

Betta Pharmaceuticals

Pfizer

NanOlogy LLC

Cardiff Oncology

Luye Pharma Group

Philogen

Hoffmann-La Roche

Regeneron Pharmaceuticals

Key Products

RYZ101

CAM2029

Voyager-V1

ADCT-701

Ramucirumab

PM8002

N-803

ONC201

Lenvatinib

Iadademstat

HA121-28

CVM-1118

Vorolanib

Talazoparib

NanoPac

Onvansertib

LY01610

Daromun

Atezolizumab

CMP-001

Please Note: It will take 3-4 business days to complete the report upon order confirmation.